Zimmer Biomet Logo

PDF Download PDF    Print page    Email page    Add to Briefcase Add to briefcase
« Previous Release | Next Release »

Zimmer Biomet Showcases New Product Innovation, Novel Digital Health Offering and Robotic Technology at AAOS 2017

WARSAW, Ind., March 14, 2017 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced plans to highlight its latest commercial offerings and preview its next generation of technological innovations at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting this week in San Diego, CA.  The Company's state-of-the-art booth (#4333) will feature an immersive and interactive tour of its newly launched digital technology and clinical services offering, Zimmer Biomet Signature Solutions, alongside more than 50 new products from its vast and diversified portfolio.

"We're proud and excited to showcase our most innovative new commercial offerings to the largest gathering of orthopaedic professionals," said David Dvorak, President and CEO of Zimmer Biomet. "New this year is a virtual booth experience designed to bring Zimmer Biomet Signature Solutions to life through a guided tour, a sneak preview of our emerging robotics platform and other technologies in our deep pipeline."

Following is a snapshot of the key highlights being featured at the Zimmer Biomet booth (#4333) at AAOS 2017:

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.  

Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC.  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Accordingly, such forward-looking statements speak only as of the date made.  Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this news release.

i Concept device - not for sale in the US

ii 1. According to NJR data from 2003 to 2015 where 9,573 Trabecular Metal and 30,452 non-Trabecular Metal cups were used in revision THA and based on hazard ratios adjusted by patient gender, age group, and indications (OA/non-OA).

2. NJR data shows a higher percentage of TM cups were used with antibiotic bone cement compared to all other non-TM cementless cups.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-biomet-showcases-new-product-innovation-novel-digital-health-offering-and-robotic-technology-at-aaos-2017-300423442.html

SOURCE Zimmer Biomet Holdings, Inc.

News Provided by Acquire Media

Close window | Back to top